Clinical Trial Update: Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sequential or upfront triple therapy with durvalumab, tremelimumab, and bevacizumab for non-resectable hepatocellular car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Enrico De Toni | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING